Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Cited In for PubMed (Select 11289126)


A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Force T, Kelly WK.

Am J Cancer Ther Pharmacol. 2014 Sep 7;2(1):21-32.


Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S.

Oncogene. 2014 Nov 10. doi: 10.1038/onc.2014.360. [Epub ahead of print]


The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review).

Chen W, Mao K, Liu Z, Dinh-Xuan AT.

Oncol Lett. 2014 Nov;8(5):1907-1911. Epub 2014 Aug 21.


Risks and benefits with bevacizumab: evidence and clinical implications.

Kurkjian C, Kim ES.

Ther Adv Drug Saf. 2012 Apr;3(2):59-69. doi: 10.1177/2042098611430109. Review.


A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer.

Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J, Wang L, Harris P, Chi KN.

Clin Genitourin Cancer. 2015 Apr;13(2):124-9. doi: 10.1016/j.clgc.2014.06.001. Epub 2014 Jun 8.


Markers for detection of prostate cancer.

Clarke RA, Schirra HJ, Catto JW, Lavin MF, Gardiner RA.

Cancers (Basel). 2010 Jun 4;2(2):1125-54. doi: 10.3390/cancers2021125.


Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.

Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E.

PLoS One. 2013 Oct 25;8(10):e78881. doi: 10.1371/journal.pone.0078881. eCollection 2013.


A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.

Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3.


Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.

Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, Figg WD.

Urol Oncol. 2014 Jan;32(1):31.e25-33. doi: 10.1016/j.urolonc.2012.11.017. Epub 2013 Feb 21.


Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Lee RJ, Smith MR.

Cancer J. 2013 Jan-Feb;19(1):90-8. doi: 10.1097/PPO.0b013e318281e280. Review.


Combined Dynamic Alterations in Urinary VEGF Levels and Tissue ADAM9 Expression as Markers for Lethal Phenotypic Progression of Prostate Cancer.

Pen CC, Liu CM, Lin CC, Lin CC, Hsieh TF, Josson S, He YC, Chung LW, Lin KL, Sung SY.

Chin J Physiol. 2012 Dec 31;55(6):390-7. doi: 10.4077/CJP.2012.BAA075.


Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.

J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.


Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.

Atkinson TM, Halabi S, Bennett AV, Rogak L, Sit L, Li Y, Kaplan E, Basch E; Cancer and Leukemia Group B.

Pain Med. 2012 Nov;13(11):1417-24. doi: 10.1111/j.1526-4637.2012.01498.x. Epub 2012 Oct 30.


Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ.

J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.


Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG.

Oncologist. 2012;17(2):212-9. doi: 10.1634/theoncologist.2011-0321. Epub 2012 Feb 2.


Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Gallick GE, Corn PG, Zurita AJ, Lin SH.

Future Med Chem. 2012 Jan;4(1):107-19. doi: 10.4155/fmc.11.161.


A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):87-92. doi: 10.1038/pcan.2011.49. Epub 2011 Oct 18.


A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; Cancer and Leukemia Group B.

Cancer. 2011 Feb 1;117(3):526-33. doi: 10.1002/cncr.25421. Epub 2010 Sep 22.


Angiogenesis inhibitors in the treatment of prostate cancer.

Hwang C, Heath EI.

J Hematol Oncol. 2010 Aug 2;3:26. doi: 10.1186/1756-8722-3-26. Review.


Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.

Corcoran NM, Hovens CM, Michael M, Rosenthal MA, Costello AJ.

Br J Cancer. 2010 Aug 10;103(4):462-8. doi: 10.1038/sj.bjc.6605798. Epub 2010 Jul 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk